BioCryst Pharmaceuticals Inc. (BCRX) Rating Reiterated by FBR & Co
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)‘s stock had its “buy” rating restated by investment analysts at FBR & Co in a note issued to investors on Tuesday. They presently have a $6.00 target price on the biotechnology company’s stock. FBR & Co’s price target would indicate a potential upside of 19.52% from the company’s current price.
BCRX has been the subject of several other research reports. JMP Securities cut BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 4th. Zacks Investment Research cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 4th. Jefferies Group boosted their price target on BioCryst Pharmaceuticals from $2.00 to $3.00 and gave the company a “hold” rating in a research note on Friday, August 5th. HC Wainwright reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. One analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the company’s stock. BioCryst Pharmaceuticals currently has an average rating of “Hold” and an average price target of $7.93.
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 5.02 on Tuesday. BioCryst Pharmaceuticals has a 52 week low of $1.63 and a 52 week high of $10.98. The stock has a 50 day moving average price of $4.40 and a 200 day moving average price of $3.77. The stock’s market capitalization is $369.97 million.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, November 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08. BioCryst Pharmaceuticals had a negative net margin of 313.02% and a negative return on equity of 232.12%. The company earned $7.80 million during the quarter, compared to analysts’ expectations of $5.94 million. During the same quarter in the previous year, the company earned ($0.20) earnings per share. The firm’s revenue for the quarter was down 29.1% on a year-over-year basis. On average, equities research analysts expect that BioCryst Pharmaceuticals will post ($0.95) EPS for the current year.
In related news, major shareholder Bros. Advisors Lp Baker sold 4,046,590 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $5.00, for a total value of $20,232,950.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Thomas R. Staab II sold 5,864 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Friday, August 12th. The shares were sold at an average price of $5.18, for a total value of $30,375.52. Following the completion of the sale, the insider now directly owns 128,745 shares in the company, valued at approximately $666,899.10. The disclosure for this sale can be found here. 5.80% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in the stock. BlackRock Group LTD raised its stake in shares of BioCryst Pharmaceuticals by 4.4% in the third quarter. BlackRock Group LTD now owns 23,530 shares of the biotechnology company’s stock worth $104,000 after buying an additional 984 shares in the last quarter. Creative Planning increased its position in BioCryst Pharmaceuticals by 48.8% in the third quarter. Creative Planning now owns 24,400 shares of the biotechnology company’s stock worth $108,000 after buying an additional 8,000 shares in the last quarter. Janney Montgomery Scott LLC increased its position in BioCryst Pharmaceuticals by 1.0% in the second quarter. Janney Montgomery Scott LLC now owns 25,935 shares of the biotechnology company’s stock worth $268,000 after buying an additional 250 shares in the last quarter. Wells Fargo & Company MN increased its position in BioCryst Pharmaceuticals by 29.8% in the third quarter. Wells Fargo & Company MN now owns 28,330 shares of the biotechnology company’s stock worth $125,000 after buying an additional 6,500 shares in the last quarter. Finally, BlackRock Advisors LLC increased its position in BioCryst Pharmaceuticals by 14.4% in the third quarter. BlackRock Advisors LLC now owns 37,886 shares of the biotechnology company’s stock worth $167,000 after buying an additional 4,772 shares in the last quarter. 70.29% of the stock is currently owned by institutional investors and hedge funds.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Stock Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.